A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension

• Primary Open Angle Glaucoma
• Ocular Hypertension

• Drug: latanoprost 75 ug
  

  Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).

  Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.

• Drug: latanoprost 100 ug
  

  Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).

  Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.

• Drug: latanoprost 125 ug
  

  Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).

  Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.

• Drug: latanoprost 50 ug
  

  Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).

  Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.

• Experimental: latanoprost 75 ug
  
  Intervention: Drug: latanoprost 75 ug
• Experimental: latanoprost 100 ug
  
  Intervention: Drug: latanoprost 100 ug
• Experimental: latanoprost 125 ug
  
  Intervention: Drug: latanoprost 125 ug
• Active Comparator: latanoprost 50 ug
  
  Intervention: Drug: latanoprost 50 ug

Inclusion Criteria:

• Male or female, 18 years of age or older.
• Primary open angle glaucoma (POAG) or ocular hypertension (OHT) requiring unilateral or bilateral administration of intraocular pressure (IOP) lowering treatment, including patients who were naïve to IOP lowering treatment.
• IOP between ? 24 mmHg and ? 36 mmHg in at least one eye at the 8 AM time point at baseline/randomization.

Exclusion Criteria:

• Closed/barely open anterior chamber angle or a history of acute angle closure.
• A history of discontinued prostaglandin IOP lowering treatment, unless the reason for discontinuation was participation in a clinical study.
• Ocular surgery or argon laser trabeculoplasty in one or both eyes within 3 months prior to the screening visit.
• Use or anticipated requirement during the study of any topical medication that was known to affect IOP.
• Anticipated need to modify systemic medication known to affect IOP (eg, beta-adrenergic antagonists, alpha-adrenergic agonists, calcium channel blockers, angiotension converting enzyme inhibitors, and angiotension II receptor antagonists) during the study period.